| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B | $1.48B | $1.03B | $718.50M |
| Cost of Revenue | $1.59B | $1.33B | $1.03B | $768.00M | $646.60M | $544.50M | $367.70M | $226.40M |
| Gross Profit | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B | $931.50M | $663.90M | $492.10M |
| Gross Margin | 60.46% | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% |
| Operating Expenses | $1.84B | $1.69B | $1.49B | $1.41B | $980.60M | $789.20M | $850.20M | $534.60M |
| Operating Income | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M | $142.30M | $-186.30M | $-42.50M |
| Operating Margin | 14.88% | 16.50% | 13.44% | 10.86% | 15.54% | 9.64% | -18.06% | -5.92% |
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M | $101.10M | $-127.10M | $-50.20M |
| Net Margin | 14.29% | 14.95% | 11.73% | 8.86% | 25.62% | 6.85% | -12.32% | -6.99% |
| EPS (Basic) | $1.46 | $1.44 | $0.88 | $0.56 | $1.31 | $0.28 | $-0.36 | $-0.15 |
| EBITDA | $945.70M | $916.70M | $565.30M | $377.50M | $376.80M | $213.20M | $-74.70M | $-19.70M |
| Stock Option Compensation Expense | $170.40M | $150.80M | $126.50M | $113.40M | $119.40M | $102.70M | $101.90M | $106.20M |
| Price To Earnings Ratio | 54.61 | 88.46 | 129.24 | 239.45 | 70.71 | 197.12 | -83.13 | -98.68 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $31.47B | $47.90B | $44.10B | $51.94B | $34.90B | $19.93B | $10.57B | $4.95B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $6.48B | $6.26B | $5.39B | $4.93B | $4.29B | $2.40B | $1.92B | $904.10M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.38B | $4.20B | $3.26B | $2.89B | $2.46B | $1.51B | $1.25B | $484.70M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $2.10B | $2.07B | $2.13B | $2.04B | $1.83B | $882.60M | $663.30M | $419.40M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.10B | $2.07B | $2.13B | $2.04B | $1.83B | $882.60M | $663.30M | $419.40M |
| Total Liabilities & Stockholders Equity | $6.48B | $6.26B | $5.39B | $4.93B | $4.29B | $2.40B | $1.92B | $904.10M |
| Book Value Per Share | $5.20 | $5.36 | $5.47 | $5.28 | $4.84 | $2.42 | $1.88 | $1.21 |
| Tangible Book Value Per Share | $4.88 | $4.95 | $4.96 | $5.13 | $4.73 | $2.37 | $1.83 | $1.18 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 8.89% | 8.64% | 6.33% | 4.40% | 11.50% | 4.22% | -6.63% | -5.55% |
| Return on Equity | 27.40% | 26.18% | 16.01% | 10.62% | 27.02% | 11.45% | -19.16% | -11.97% |
| Return on Invested Capital | 10.20% | 9.63% | 7.86% | 5.30% | 8.11% | 6.74% | -11.00% | -5.55% |
| Quick Ratio | 1.28 | 2.48 | 1.83 | 4.62 | 5.19 | 5.13 | 7.32 | 5.04 |
| Current Ratio | 1.47 | 2.84 | 1.99 | 5.11 | 5.58 | 5.47 | 7.64 | 5.36 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M | $101.10M | $-127.10M | $-50.20M |
| Depreciation | $217.70M | $186.00M | $155.90M | $101.90M | $67.10M | $48.70M | $29.10M | $16.10M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $989.50M | $748.50M | $669.50M | $442.50M | $475.60M | $314.50M | $123.20M | $92.00M |
| Capital Expenditures | $358.80M | $236.60M | $364.80M | $389.20M | $199.00M | $180.00M | $67.10M | $66.00M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $750.00M | $688.70M | $557.70M | $0.00 | $0.00 | $0.00 | $100.00M | $0.00 |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $630.70M | $511.90M | $304.70M | $53.30M | $276.60M | $134.50M | $56.10M | $26.00M |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Why it moved over time
Dexcom (DXCM) reported strong Q2 results and raised FY26 guidance, signaling G7 adoption, margin expansion and ongoing buybacks that support accelerating revenue and earnings visibility.
Key fact: Q2: 13.1% revenue growth and 49.7% operating income growth; company raised FY26 guidance.
seekingalpha.com: DexCom: Still A Cautious Buy Following EarningsDexcom reported Q2 revenue up 13% to $1.31 billion, beat EPS estimates and raised full-year revenue guidance, signaling sustained demand for its continuous glucose monitors and an improved outlook.
Key fact: Q2 revenue $1.31 billion (+13% y/y); EPS $0.70 vs. $0.61 estimate; raised full-year revenue forecast.
gurufocus.com: DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Signal Robust MomentumInvestors are focused on DexCom's upcoming Q2 earnings and guidance, as analyst coverage highlights margin pressure from tariffs and inflation plus G7 adoption and reimbursement expansion that could affect revenue and margins.
Key fact: Recent coverage (Zacks, other outlets) emphasizes Q2 results will reflect G7 adoption, broader reimbursement and potential margin pressure from tariffs and inflation.
fool.com: 3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold